Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.
Lead Product(s): CAS 139481-59-7
Therapeutic Area: Genetic Disease Product Name: AC-203
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Winhealth Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 06, 2021